Press Releases

Definiens Late Breaking Abstract Title Makes Top 4 “Novel Data You Must See” presentations by Society for Immunotherapy of Cancer

Tissue quantification identifies patient populations

Munich, Germany – [8.Nov.2016] – Definiens, the leader in Tissue Phenomics® solutions from biomarker discovery to meaningful diagnostics today announced a Late Breaking Abstract that contributes to the scientific exchange and education at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting.

Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens will be presenting a late breaking abstract entitled, “Combinatorial CD8+ and PD-L1+ cell densities correlate with response and improved survival in NSCLC patients treated with durvalumab”.

Definiens’ products and services deepen the understanding of disease biology and the immune system to advance clinical trials. Using Tissue Phenomics, data can be analyzed to find meaningful tissue signatures. In this presentation, the potential of multiple biomarkers was assessed to identify patient populations responding to an anti- PD-L1 treatment.

“By constantly advancing the Tissue Phenomics methodology, we are able to discover novel prognostic and predictive algorithms with superior prediction performance,” said Günter Schmidt, Vice President of Research at Definiens. “Integrating image analysis and clinical data into a single Big Data workflow tremendously accelerates the discovery process. This enables us to optimize all model parameters, gaining insight into the disease and predicting the impact of treatment with high accuracy.”

The research results will be summarized in the talk given at the 2016 SITC Annual Meeting, a conference that brings together over 2,400 people worldwide:

Combinatorial CD8+ and PD-L1+ cell densities correlate with response and improved survival in NSCLC patients treated with durvalumab 

Speaker: Sonja Althammer, PhD Session: Late-Breaking Abstract Session I Date & Time: Friday, November 11, 2016 @ Noon EST

Definiens Technology enabled us to quantify CD8(+) and PD-L1(+) cell densities. We show that patients with high pre-treatment CD8(+) and PD-L1(+) cell densities have improved Objective Response Rate (ORR), Overall Survival (OS), and Progression Free Survival (PFS) compared to those with high CD8(+) or high PD-L1(+) cell densities alone. These findings should be confirmed by an independent study.

In addition, Definiens will be presenting the following Posters:

1.    Poster 109 

Title: Spatial distribution of CD8+ T cells predicts response to ipilimumab in malignant melanoma (Günter Schmidt)

2.    Poster 110 

Title: Tumor-associated macrophages as a prognostic marker for prostate cancer progression (Günter Schmidt)

More information about Definiens products and services may be found at Booth #417.

The 31st Annual SITC Meeting & Associated Programs 2016 will be held from November 9-13, 2016 at the Gaylord National Hotel & Conference Center in National Harbor, Maryland. For more information about SITC 2016, click here.

About Definiens

We improve patient lives by unlocking the tissue phenome. In oncology, therapeutic strategies have shifted from a direct assault on cancer cells to recruiting the immune system for that purpose. Our mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer-relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies. Our vision is to create unique patient profiles for an individualized standard of care, where patients experience fewer side effects and live longer.

Definiens' Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com.

Definiens is a member of the AstraZeneca group providing products and services to companies across the life sciences sector, including MedImmune, the global biologics research and development arm of AstraZeneca.

For more information, please visit: www.definiens.com.